Researchers at Tel Aviv University have developed an innovative drug delivery system that enhances the efficacy of cancer treatments by simultaneously administering two therapeutic agents directly to tumors. This approach addresses the challenge of differing drug properties, such as degradation rates and circulation times, which can hinder the synchronized arrival of medications at the tumor site. By encapsulating two cancer-fighting drugs within biodegradable nanoparticles, the team ensures that both agents reach the tumor concurrently, maximizing their combined therapeutic impact while minimizing potential side effects. These nanoparticles are engineered to target P-selectin, a protein prevalent on cancer cells and the new blood vessels they form, facilitating precise delivery to the tumor.
In preclinical studies involving 3D cancer cell models and animal subjects, this dual-drug delivery system demonstrated significant tumor reduction and extended progression-free periods by 2.5 times compared to standard treatments. Notably, mice treated with the nanoparticle-encapsulated drugs exhibited double the lifespan of those receiving unencapsulated medications and triple that of untreated controls. The nanoparticles also successfully traversed the blood-brain barrier, effectively targeting brain metastases without harming healthy brain tissue. These promising results suggest that this platform could be adapted for other cancers, including glioblastoma and pancreatic cancer, potentially advancing the field of oncology therapeutics. Click for More Details
